Open AccessThrombopoietin receptor agonist for treatment of immune thrombocytopenia in pregnancy: a narrative review
Author(s) -
Nikki Agarwal,
Ankit Mangla
Publication year - 2021
Publication title -
therapeutic advances in hematology
Language(s) - English
Resource type - Journals
eISSN - 2040-6215
pISSN - 2040-6207
DOI - 10.1177/20406207211001139
Subject(s) - medicine , eltrombopag , thrombopoietin , pregnancy , azathioprine , rituximab , romiplostim , danazol , thrombopoietin receptor , vincristine , cyclophosphamide , pediatrics , chemotherapy , immune thrombocytopenia , platelet , lymphoma , endometriosis , disease , genetics , stem cell , haematopoiesis , biology
The treatment of immune thrombocytopenia (ITP) in adults has evolved rapidly over the past decade. The second-generation thrombopoietin receptor agonists (TPO-RAs), romiplostim, eltrombopag, and avatrombopag are approved for the treatment of chronic ITP in adults. However, their use in pregnancy is labeled as category C by the United States Food and Drug Administration (FDA) due to the lack of clinical data on human subjects. ITP is a common cause of thrombocytopenia in the first and second trimester of pregnancy, which not only affects the mother but can also lead to thrombocytopenia in the neonatal thrombocytopenia secondary to maternal immune thrombocytopenia (NMITP). Corticosteroids, intravenous immunoglobulins (IVIGs) are commonly used for treating acute ITP in pregnant patients. Drugs such as rituximab, anti-D, and azathioprine that are used to treat ITP in adults, are labeled category C and seldom used in pregnant patients. Cytotoxic chemotherapy (vincristine, cyclophosphamide), danazol, and mycophenolate are contraindicated in pregnant women. In such a scenario, TPO-RAs present an attractive option to treat ITP in pregnant patients. Current evidence on the use of TPO-RAs in pregnant women with ITP is limited. In this narrative review, we will examine the preclinical and the clinical literature regarding the use of TPO-RAs in the management of ITP in pregnancy and their effect on neonates with NMITP.